Case type Dangerous Drugs & Pharmaceutical Liability

Tepezza Hearing Loss & Tinnitus

Close-up of a hearing aid behind the ear of an older man wearing glasses.

Lost hearing or developed ringing in your ears after Tepezza infusions? Tell us your story.

CBW Law reviews claims from people treated with Tepezza (teprotumumab) for thyroid eye disease who were left with hearing loss or tinnitus. Tell Us Your Story. Contacting us does not create an attorney-client relationship.

Tell Us Your Story Call (800) 476-2416

Tepezza is an infusion drug for thyroid eye disease. Its label now warns that it may cause severe hearing impairment, including hearing loss that in some cases may be permanent1. That warning was added in July 20232. Federal lawsuits claiming Tepezza caused permanent hearing loss and tinnitus are coordinated in Chicago. A Tepezza attorney looks at hearing tests before, during and after treatment.

What the Tepezza label says about hearing

Tepezza (teprotumumab-trbw) treats thyroid eye disease, a condition that can push the eyes forward and cause double vision. It is given as eight infusions, one every three weeks1. The FDA first approved it in January 20203.

On July 17, 2023, the FDA approved a labeling supplement that added a Warnings and Precautions entry on hearing2. The current label says Tepezza may cause severe hearing impairment, including hearing loss, which in some cases may be permanent. It tells doctors to assess hearing before, during and after treatment and to weigh benefits and risks1.

Hearing numbers in the label

Early placebo-controlled trials
Hearing impairment in 10% of Tepezza patients (8 of 84) and none of 86 on placebo1
Post-approval trials
Hearing impairment in 19% during the treatment period1
What counted
Includes hearing loss, tinnitus, muffled or distorted hearing and eustachian tube problems1

Trial rates describe groups of patients. They do not predict what happened to any one person.

What studies have found

Doctors have published studies on hearing after Tepezza. Two examples:

  • A case series of 22 patients with hearing tests before and after treatment found that 11 met criteria for ototoxicity, or drug-related hearing damage, in at least one ear. Losses were greatest at high frequencies and more likely in older patients4.
  • A study of 131 patients at six centers found ear and balance problems in 30.5%. Four people stopped treatment because of hearing loss, and 46% had at least one side effect still present at their last visit5.

These are observational studies. They show patterns in groups and do not settle what caused hearing loss in a particular patient. Age, noise exposure and other conditions also affect hearing.

The Tepezza lawsuits

In June 2023 the Judicial Panel on Multidistrict Litigation sent federal Tepezza cases to the Northern District of Illinois before Judge Thomas M. Durkin as MDL No. 30796. The Panel said the cases claim Tepezza causes permanent hearing loss and tinnitus and share questions about causation, testing and the adequacy of the label. These are allegations, not findings.

MDL 3079 at a glance

Court
Northern District of Illinois, Judge Thomas M. Durkin6
Cases pending
279 as of Nov. 2, 2026 (289 filed in total)7
At centralization
37 cases pending in eight districts6

An MDL coordinates individual cases for pretrial work. It is not a class action or a settlement8.

Hearing injuries involved

  • Sensorineural hearing loss confirmed by an audiogram
  • Tinnitus, or ringing or buzzing in the ears
  • Muffled hearing or a blocked feeling
  • Sensitivity to sound
  • Hearing aids or other treatment after the infusions

Who may have a Tepezza claim

A review usually asks:

  • How many Tepezza infusions you had, and the dates
  • Whether you had a hearing test before treatment
  • When hearing changes started, and what later tests showed
  • Whether the changes went away or stayed
  • Other hearing risks, such as noise exposure or earlier ear problems

Hearing changes that began before July 2023, when the label first carried the hearing warning, can raise different questions than later ones. You do not need every record before contacting us.

Who may be responsible

An investigation may look at the company that developed and sold Tepezza and at what it knew about hearing risks, and when. The infusion center and treating doctors usually supply the records that show the timeline.

Filing deadlines for Tepezza lawsuits

Deadlines depend on your state and on when you learned of the injury and its possible cause. Examples:

  • Arizona: generally two years for personal injury and wrongful death9.
  • California: two years for injury to or death of a person caused by another's wrongful act or neglect10.
  • New York: three years for personal injury11, with a separate rule that runs from discovery for injuries caused by the latent effects of exposure to a substance in the body12.
  • Texas: two years for personal injury and wrongful death13, and most product liability claims must be brought within 15 years of the product's sale, with an exception for certain latent diseases14.

When the clock starts can depend on when a person knew, or should have known, about the injury and its possible link to the medicine. Rules for children, wrongful death and claims against public hospitals can differ. Ask a Tepezza attorney to check the rules for your state early, before records are lost.

Tell Us Your Story →

Records that help a Tepezza review

Records worth gathering

Treatment

  • Infusion records and dates
  • Ophthalmology or endocrinology notes
  • Any consent forms

Hearing

  • Audiograms before and after
  • ENT or audiology notes
  • Hearing aid records

Impact

  • Bills and insurance statements
  • Work or daily-life limits
  • Notes on when symptoms began

What happens after you contact CBW Law

How a review works

  1. Tell us what happened

    Share what you remember about your infusions and your hearing. You do not need every record first.

  2. We build the timeline

    We line up your infusion dates with any hearing tests and symptoms.

  3. We gather records

    With your permission, we request pharmacy, medical and billing records from the places that treated you.

  4. We explain what we see

    We tell you what the records show, what questions remain and what options may be open, including deadlines.

Hearing loss has many causes. A Tepezza claim depends on the infusion dates, the hearing tests and what your doctors found.

Plain English

Medical, Health & Insurance

Terms you may see in a Tepezza hearing case.

Condition and drug

Thyroid eye disease
An autoimmune condition that inflames tissue behind the eyes.
Teprotumumab
The drug in Tepezza, given by IV infusion.

Hearing terms

Audiogram
A hearing test chart showing the softest sounds you can hear at each pitch.
Sensorineural hearing loss
Hearing loss from inner-ear or nerve damage.
Tinnitus
Ringing, buzzing or hissing in the ears.
Ototoxicity
Damage to hearing or balance caused by a drug4.

Care and coverage

ENT
An ear, nose and throat doctor.
Hearing aid coverage
Many health plans limit hearing aid coverage, so check your plan.

Questions

Tepezza lawsuit questions

Short answers to the questions people ask first.

Is there a Tepezza hearing loss lawsuit?

Yes. Federal Tepezza cases claiming hearing loss and tinnitus are coordinated in MDL No. 3079 in Chicago.

Does Tepezza always cause hearing loss?

No. Trials found hearing impairment in a minority of patients. A Tepezza lawyer looks at your own tests and timeline.

What if my hearing came back?

Temporary changes are reviewed differently from lasting loss. A Tepezza attorney will ask what later tests showed.

I never had a hearing test before treatment. Can I still ask?

Yes. Other records, such as earlier exams or notes, can help show your hearing before treatment.

When did the label start warning about hearing?

The FDA approved the hearing warning on July 17, 2023.

Is the Tepezza MDL a class action?

No. It coordinates individual lawsuits for pretrial work.

How long do I have to file a Tepezza lawsuit?

It depends on your state and on when you learned about the hearing loss and its possible link to Tepezza.

Should I stop Tepezza if I notice hearing changes?

Tell your doctor right away. Treatment decisions belong to you and your doctor.

Does tinnitus alone count?

It can be part of a claim. A Tepezza lawyer looks at how long it has lasted and how it is documented.

What does it cost to contact CBW Law?

Telling us your story costs nothing, and contacting us does not create an attorney-client relationship.

Tell Us Your Story

If Tepezza infusions left you with hearing loss or constant ringing in your ears, a Tepezza attorney can review your records.

Tell us what happened. CBW Law will review your information and explain what we see. Submitting information does not establish an attorney-client relationship or guarantee representation.

Tell Us Your Story Call (800) 476-2416

This page is general information about Tepezza and hearing. It is not legal or medical advice and does not create an attorney-client relationship. Hearing loss has many causes, and a label warning or an MDL does not by itself establish that Tepezza caused any person's injury. Talk to your doctor before changing any treatment. Laws and deadlines differ by state, and no outcome can be promised.

Keep reading

Official resources

Government sources for safety notices, labels and reporting.

Government

DailyMed, National Library of Medicine

Current FDA-approved labels for prescription and OTC medicines.

Government

MedWatch: report a problem with a medicine, FDA

Tell the FDA about a side effect or a product problem.

Government

Hearing Loss, NIDCD (NIH)

Plain-language information on hearing loss and tinnitus.

Government

Tepezza approval history, Drugs@FDA

FDA approval and labeling actions for BLA 761143.

Court

Pending MDLs, JPML

Current federal multidistrict litigation statistics.

Apparatus

Sources & Cited Articles

The source material behind each factual, medical and legal statement on this page, numbered to match the markers in the text.

  1. TEPEZZA (teprotumumab-trbw) prescribing informationHorizon Therapeutics USA; DailyMed, National Library of Medicine · Label revised 9/2026; verified Nov 12, 2026Section 5.4 hearing impairment warning; dosing; Table 1 (hearing impairment 10% vs 0%); 19% in post-approval trials; term definition.
  2. Supplement approval letter, BLA 761143/S-023U.S. Food and Drug Administration · July 17, 2023; verified Nov 12, 2026Approves additions to Warnings and Precautions, Adverse Reactions and Patient Counseling (hearing impairment).
  3. Drugs@FDA: BLA 761143 (Tepezza)U.S. Food and Drug Administration · Approval history; verified Nov 12, 2026Original approval Jan. 21, 2020; later labeling supplements.
  4. Frequency and Patterns of Hearing Dysfunction in Patients Treated with TeprotumumabOphthalmology 2024;131(1):30-36 (Keen et al.) · PMID 37567417; abstract read; verified Nov 12, 2026Case series of 22 patients; 11 met ototoxicity criteria in at least one ear; high-frequency and age effects.
  5. Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter StudyOphthalmology 2024;131(4):458-467 (Shah et al.) · PMID 37852417; abstract read; verified Nov 12, 2026131 patients; ear and labyrinth events 30.5%; 4 stopped for hearing loss; 46% had a persistent event.
  6. Transfer Order, In re Tepezza Marketing, Sales Practices, and Products Liability Litigation, MDL No. 3079Judicial Panel on Multidistrict Litigation · Filed June 2, 2023; verified Nov 12, 2026Centralizes cases in N.D. Ill. before Judge Durkin; describes hearing loss and tinnitus allegations; 37 cases in eight districts.
  7. Pending MDL Dockets by Actions Pending (report date Nov. 2, 2026)United States Judicial Panel on Multidistrict Litigation · JPML statistics report; verified Nov 12, 2026Lists each pending MDL with its court, judge, actions now pending and total actions.
  8. About the PanelUnited States Judicial Panel on Multidistrict Litigation · JPML; verified Nov 12, 2026Centralizes federal cases sharing common questions of fact for coordinated pretrial proceedings; cases not resolved are remanded.
  9. A.R.S. § 12-542Arizona State Legislature · Arizona Revised Statutes; verified Nov 12, 2026Two years for injury to the person and for wrongful death.
  10. Code of Civil Procedure § 335.1California Legislature · California Code; verified Nov 12, 2026Two years for injury to or death of an individual caused by the wrongful act or neglect of another.
  11. Civil Practice Law and Rules § 214New York State Senate · Consolidated Laws of New York; verified Nov 12, 2026Three years for personal injury.
  12. Civil Practice Law and Rules § 214-cNew York State Senate · Consolidated Laws of New York; verified Nov 12, 2026Latent effects of exposure to a substance: three years computed from discovery of the injury.
  13. Civil Practice and Remedies Code § 16.003Texas Legislature · Texas Statutes; verified Nov 12, 2026Two years for personal injury and wrongful death.
  14. Civil Practice and Remedies Code § 16.012Texas Legislature · Texas Statutes; verified Nov 12, 2026Products liability actions within 15 years of sale, with an exception for certain latent diseases from exposure.

Accountability

Reviewed by

Craig Weiss, founder and managing attorney of CBW Law Firm

Craig Weiss

Managing Attorney · CBW Law

View full profile →

Attorney advertising. The content of this website may be considered attorney advertising under the rules of certain jurisdictions. The information on this website is for general information purposes only and should not be taken as legal advice for any individual case or situation. Viewing this site does not create an attorney-client relationship. Prior results do not guarantee a similar outcome. Statutes, regulations and case law change, and the law differs from state to state.